At a glance
ClinicalIndex Comparison RecordN/ACompleted· 25 enrolled
Drug / intervention
TheraSphere® Yttrium-90 (Y-90) Microspheresdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres As First-Line Treatment For Cholangiocarcinoma
H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Dec 3, 2010·Updated Mar 22, 2017
In Brief
A clinical study evaluating TheraSphere® Yttrium-90 (Y-90) Microspheres for Cholangiocarcinoma. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The purpose of this study is to see if Therasphere will be a better way to treat cholangiocarcinoma. The investigators want to find out what effects, good and/or bad, this treatment will have on the patient and their cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCholangiocarcinoma
CountriesUnited States
CollaboratorsBTG International Inc.
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartJan 2011
Primary CompletionAug 2015
TodayJul 2026
First PostedDec 3, 2010
Enrollment StartJan 1, 2011
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 15.6 years ago
Interventions
TheraSphere® Yttrium-90 (Y-90) Microspheresdevice
Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver.